774 related articles for article (PubMed ID: 28898698)
1. Enhancing CD8
Zhang Y; Kurupati R; Liu L; Zhou XY; Zhang G; Hudaihed A; Filisio F; Giles-Davis W; Xu X; Karakousis GC; Schuchter LM; Xu W; Amaravadi R; Xiao M; Sadek N; Krepler C; Herlyn M; Freeman GJ; Rabinowitz JD; Ertl HCJ
Cancer Cell; 2017 Sep; 32(3):377-391.e9. PubMed ID: 28898698
[TBL] [Abstract][Full Text] [Related]
2. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
3. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
[TBL] [Abstract][Full Text] [Related]
4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
6. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
7. Fatty Acid Oxidation Controls CD8
Lin R; Zhang H; Yuan Y; He Q; Zhou J; Li S; Sun Y; Li DY; Qiu HB; Wang W; Zhuang Z; Chen B; Huang Y; Liu C; Wang Y; Cai S; Ke Z; He W
Cancer Immunol Res; 2020 Apr; 8(4):479-492. PubMed ID: 32075801
[TBL] [Abstract][Full Text] [Related]
8. Characterization of CD103
Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
[TBL] [Abstract][Full Text] [Related]
9. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
10. PD-1
Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
[No Abstract] [Full Text] [Related]
11. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
12. Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.
Danahy DB; Kurup SP; Winborn CS; Jensen IJ; Harty JT; Griffith TS; Badovinac VP
J Immunol; 2019 Aug; 203(3):725-735. PubMed ID: 31189573
[TBL] [Abstract][Full Text] [Related]
13. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
14. Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8
Gemta LF; Siska PJ; Nelson ME; Gao X; Liu X; Locasale JW; Yagita H; Slingluff CL; Hoehn KL; Rathmell JC; Bullock TNJ
Sci Immunol; 2019 Jan; 4(31):. PubMed ID: 30683669
[TBL] [Abstract][Full Text] [Related]
15. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
16. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
18. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
19. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment.
Qiao G; Chen M; Mohammadpour H; MacDonald CR; Bucsek MJ; Hylander BL; Barbi JJ; Repasky EA
Cancer Immunol Res; 2021 Jun; 9(6):651-664. PubMed ID: 33762351
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]